Clinical Study Shows Targeted End-tidal Control Anesthesia Delivery Improves Efficiency and Accuracy to Help Optimize Patient Care

GE HealthCare (Nasdaq: GEHC) today announced the publication of the MASTER trial results in the peer-reviewed journal Anesthesia and Analgesia, demonstrating the safety and efficacy of End-tidal Control software for inhaled anesthetic administration for surgical patients.^1* End-tidal Control software automatically achieves and maintains clinician-set targets of end-tidal anesthetic agent and oxygen concentrations. The results highlight End-tidal Control’s performance in achieving and maintaining targeted agent and oxygen concentrations during anesthesia delivery compared to conventional manual control.

As healthcare systems continue to face workforce challenges, sicker patients, and increasing costs and administrative demands, the need for efficient care is critical. Automation in anesthesia gas delivery can help reduce manual intervention and cognitive burden for clinicians, while decreasing costs and optimizing patient care.

To ease the way to more efficient care, automated anesthesia gas delivery can also help support low-flow anesthesia —a technique in which anesthetic gas flow is reduced to the lowest level consistent with safe patient care. “In the dynamic surgical environment, the repeated manual adjustment of fresh gas flows and anesthetic vaporizer settings required to deliver low-flow anesthesia can be challenging for anesthesia clinicians. Results from the MASTER trial showed that End-Tidal Control software was able to achieve and sustain desired oxygen and anesthetic agent concentrations more consistently and timely compared to conventional methods,” said Trial Investigator Melinda S. Seering, MD, Clinical Associate Professor of Anesthesia at University of Iowa Healthcare. “As less anesthetic agent is needed to maintain the respective targets, End-tidal Control software can help enhance patient safety in the operating room, while reducing greenhouse gas emissions and costs.”**

The randomized, controlled MASTER trial (Multi-site Anesthesia Randomized Controlled STudy of End Tidal Control Compared to Conventional Anesthesia Results) was conducted across four U.S.-based hospitals and analyzed data from 210 adult patients (18 years of age and older) scheduled for surgical procedures under general inhaled anesthesia. The study assessed the safety and efficacy of End-tidal Control software compared to conventional manual control in achieving and maintaining provider-set targets for end-tidal anesthetic agent and oxygen concentrations during patient care.